CorMedix to acquire Heron Therapeutics assets, reports Q3 2026 results
CorMedix disclosed on November 12, 2026 that it agreed on November 9 to buy substantially all of Heron's assets, alongside third-quarter revenue of $54.5 million.
SEC filing (2)
2 stories
CorMedix disclosed on November 12, 2026 that it agreed on November 9 to buy substantially all of Heron's assets, alongside third-quarter revenue of $54.5 million.
SEC filing (2)
The agency set a first-quarter 2027 PDUFA date for the antifungal's new prophylaxis use, based on the Phase III ReSPECT trial.
SEC filing